Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price increased by equities research analysts at HC ...

H.C. Wainwright raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares following ...

Axsome Therapeutics Inc. shares dipped over 2% on Tuesday — their worst session in nearly two weeks — after the company ...

Leerink Partnrs lowered their FY2028 earnings per share estimates for Axsome Therapeutics in a research note issued on ...

Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated ...

Q4 2024 Earnings Call Transcript February 18, 2025 Axsome Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Truist raised the firm’s price target on Axsome Therapeutics (AXSM) to $200 from $190 and keeps a Buy rating on the shares. The company’s Q4 ...

Axsome Therapeutics gained more than $1 billion in market value Monday, after the brain drug developer disclosed a patent ...

Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key ...

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central ...

Significant R&D investment of $55 million highlights a focus on pipeline development. Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than ...